€9.04
Your prediction
Intellia Therapeutics Inc Stock
Pros and Cons of Intellia Therapeutics Inc in the next few years
Pros
Cons
Performance of Intellia Therapeutics Inc vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Intellia Therapeutics Inc | 0.040% | 10.806% | 34.623% | -57.460% | -20.422% | -82.456% | -54.870% |
Chromadex Corp | 0.950% | -10.169% | 3.922% | 345.378% | 105.825% | 575.159% | 166.332% |
Polynovo Ltd | 1.630% | -0.794% | -11.348% | -55.986% | -48.347% | -28.977% | -61.180% |
Cardio3 Biosciences S.A. | -0.930% | 1.266% | -18.575% | 35.881% | -51.589% | -80.296% | -96.425% |
Comments
News

Analysts Think These Stocks Could More Than Double in Value
Persistent volatility has plagued the S&P 500 for much of 2025, prompting widespread caution among many investors amid the uncertainties of trade battles, tariffs, domestic policy, and more

Intellia Therapeutics Delivers a Q4 Beat
Intellia Therapeutics (NASDAQ:NTLA), a leader in gene-editing technology, delivered its fourth-quarter earnings results on Feb. 27. The company reported a net loss of $1.27 per share, which was

2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street
Biotech companies can skyrocket in a short period because of excellent clinical or regulatory progress. And if we take the word of Wall Street analysts, some of them will do precisely that in the